Adding Lynparza to Presurgical Chemo May Not Boost TNBC Outcomes
The addition of Lynparza to presurgical chemotherapy did not improve outcomes for patients with basal-like BRCA wild-type triple-negative breast cancer.
Source: curetoday.com
Trial Consortium News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Trial Consortium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Trial Consortium Today - Breaking & Trending Today
Olaparib With Chemotherapy Does Not Elicit Improved Outcomes vs Chemotherapy Alone in BRCA Wild-Type TNBC
Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.
Source: onclive.com
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed
Stockholm, Sweden, April 1, 2024 - BioArctic AB's partner Eisai announced today that Eisai has submitted a supplemental Biologics License Application for monthly lecanemab-irmb intravenous ...
Source: marketscreener.com
BioArctic's partner Eisai submits supplemental Biologics License Application to FDA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer's disease
Stockholm, January 7, 2023 - BioArctic AB's partner Eisai announced today they have submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration supporting the... | January 7, 2023
Source: marketscreener.com
Remdesivir slightly lowers death, ventilation in COVID hospital patients
The findings aren't markedly different from interim results published in February 2021.
Source: umn.edu